PARP1 and ovarian carcinoma: A phase Ib study sponsored by Astra Zeneca (NCT02511795) (Table 2) evaluating the coadministration of a highly selective WEE1 inhibitor, AZD1775, and the potent PARP inhibitor olaparib was conducted with 119 patients with refractory solid tumors, including 26 ovarian cancer patients, and was completed on October 16, 2019 [192, 194].